Bayer Completes Acquisition of Blackford Analysis Ltd

Bayer Completes Acquisition of Blackford Analysis Ltd
share Share
  • Closing follows announcement of acquisition on January 18, 2023
  • Acquisition bolsters Bayer’s position in digital medical imaging
  • Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture
Bayer announced that the company has completed the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. As a result, Blackford, which has a presence in the United Kingdom and the United States, is now a wholly owned subsidiary of Bayer AG. The company provides infrastructure and access to a rich clinical application ecosystem focused on imaging and analytics. It continues to operate on an arm’s length basis to preserve its entrepreneurial culture as an essential pillar for nurturing successful innovation. Blackford remains accountable to advance its technology, channel partnerships and ClinApp portfolio while benefiting from the experience, infrastructure and reach of Bayer as a global pharmaceutical company.

“Today’s official closing of the acquisition of Blackford marks an important step in implementing our strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow,” said Gerd Krüger, President Radiology, Bayer. “Bayer is a leader in key radiology areas with a comprehensive portfolio and a deep medical understanding across a multitude of diseases. We are excited that we are now able to join forces with the exceptional Blackford team to use our combined expertise for the benefit of patients and their treating physicians.”

“Blackford has built a strong reputation in the AI platform segment for radiology, with a wide portfolio of 3rd party products and a strong deployed base of hospitals, radiology groups and imaging centers,” said Ben Panter, Chief Executive Officer of Blackford. “Combining our knowledge and experience with Bayer will enable us to provide solutions to deliver ongoing clinical value to radiologists and their referrers.”

Source: Bayer

«« New Study Suggests Breast Cancer Patients Over 65 May Not Always Need Radiation Therapy

3D Camera Optimises Patient Positioning and Impacts Radiation Exposure »»

Published on : Mon, 13 Feb 2023

Related Articles

Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores... Read more

The future of medical imaging and the role of AI: Bayer reinforces commitment to innovation in Radiology Focus on artificial... Read more

Bayer,Acquisition,Blackford Analysis Ltd Bayer Completes Acquisition of Blackford Analysis Ltd

No comment

Please login to leave a comment...

Highlighted Products